Outcomes in patients with heart failure with preserved ejection fraction
- PMID: 24975912
- DOI: 10.1016/j.hfc.2014.04.012
Outcomes in patients with heart failure with preserved ejection fraction
Abstract
Heart failure with preserved ejection fraction (HF-PEF) represents a heterogenous group of patients with HF, more commonly affecting older women, with a history of hypertension and, less commonly, coronary disease, than patients with HF with reduced ejection fraction (HF-REF). Patients with HF-PEF have lower short-term and longer-term mortality than patients with HF-REF. At present, therapeutic interventions that have had proven benefits for patients with HF with reduced EF have not been shown to have similar benefits for patients with HF-PEF and there remains an urgent need for new therapeutic strategies to improve the clinical outcomes for patients with HF-PEF.
Keywords: Heart failure; Preserved ejection fraction; Reduced ejection fraction.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Advances in the treatment of heart failure with a preserved ejection fraction.Curr Opin Cardiol. 2008 May;23(3):233-40. doi: 10.1097/HCO.0b013e3282f73317. Curr Opin Cardiol. 2008. PMID: 18382212 Review.
-
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis.Eur Heart J. 2012 Jul;33(14):1750-7. doi: 10.1093/eurheartj/ehr254. Epub 2011 Aug 6. Eur Heart J. 2012. PMID: 21821849 Review.
-
Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort.J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):583-90. doi: 10.2459/JCM.0000000000000100. J Cardiovasc Med (Hagerstown). 2015. PMID: 25022929 Review.
-
In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22. Int J Cardiol. 2014. PMID: 24630337
-
Comorbidities and differential diagnosis in heart failure with preserved ejection fraction.Heart Fail Clin. 2014 Jul;10(3):481-501. doi: 10.1016/j.hfc.2014.04.009. Heart Fail Clin. 2014. PMID: 24975911 Review.
Cited by
-
Identifying Phenogroups in patients with subclinical diastolic dysfunction using unsupervised statistical learning.BMC Cardiovasc Disord. 2020 Aug 14;20(1):367. doi: 10.1186/s12872-020-01620-z. BMC Cardiovasc Disord. 2020. PMID: 32795252 Free PMC article.
-
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype.Nat Rev Cardiol. 2020 Aug;17(8):523-531. doi: 10.1038/s41569-019-0286-y. Epub 2019 Nov 4. Nat Rev Cardiol. 2020. PMID: 31686012 Review.
-
Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Curr Atheroscler Rep. 2015 Nov;17(11):64. doi: 10.1007/s11883-015-0541-6. Curr Atheroscler Rep. 2015. PMID: 26408016 Review.
-
Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.J Am Heart Assoc. 2017 May 2;6(5):e005231. doi: 10.1161/JAHA.116.005231. J Am Heart Assoc. 2017. PMID: 28465299 Free PMC article. Review.
-
Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy.Radiat Oncol. 2015 Jul 10;10:141. doi: 10.1186/s13014-015-0436-2. Radiat Oncol. 2015. PMID: 26159409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous